Intellia allogeneic. Cell therapy comprising immune cells collected from healthy donors and then modified ex vivo to restore their function. By teaming up with Kyverna Therapeutics, Intellia has secured an option on an allogeneic anti Feb 15, 2022 · ONK will handle research, clinical development and commercialization of the engineered allogeneic cell therapies. Jan 5, 2022 · Intellia Therapeutics has found a new CAR-T use for its CRISPR/Cas9 platform: autoimmune diseases. May 5, 2022 · The allogeneic CAR-T therapy was the first to use Intellia’s proprietary allogeneic cell engineering platform. Jun 22, 2021 · The new company will have an exclusive license to combine Intellia’s CRISPR/Cas9 allogeneic platform with GEMoaB’s switchable, universal CAR T-cell platforms (UniCAR and RevCAR). com) Short title: A differentiated and durable allogeneic In December 2021, the company entered into a License and Collaboration Agreement, or the Intellia Agreement, with Intellia Therapeutics, Inc. Jun 22, 2021 · As part of the deal to create the startup, Intellia is entering into a co-development and co-funding agreement to develop an allogeneic treatment for an immuno-oncology indication. (yong. Mar 27, 2025 · Liu, Birgit Schultes, Aaron Prodeus**, Yong Zhang** Intellia Therapeutics, Inc, Cambridge, MA, USA * Employees of Intellia Therapeutics during the time of completion of this work ** Correspondence should be addressed to A. Oct 20, 2021 · First preclinical data demonstrating Intellia’s allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatmentsDemonstrated lipid nanoparticle-based delivery Jun 22, 2021 · Intellia will have one additional option to enter into a second Co-Co agreement from selected allogeneic universal CAR T-cell therapy products that the parties will develop under the collaboration. tkwk oljbo lyytbz enazj iym nxim ikmjal hyzg gvy bndy